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Prostate cancer is a gland tumor in the male reproductive system. It is a multifaceted and genomically complex
disease. Transmembrane protease, serine 2 and v-ets erythroblastosis virus E26 homolog (TMPRSS2-ERG) gene fusions are
the common molecular signature of prostate cancer. Although tremendous advances have been made in unraveling
various facets of TMPRSS2-ERG-positive prostate cancer, many research findings must be sequentially collected and
re-interpreted. It is important to understand the activation or repression of target genes and proteins in response to
various stimuli and the assembly in signal transduction in TMPRSS2-ERG fusion-positive prostate cancer cells. Accordingly,
we divide this multi-component review ofprostate cancer cells into several segments: 1) The role of TMPRSS2-ERG fusion
in genomic instability and methylated regulation in prostate cancer and normal cells; 2) Signal transduction cascades in
TMPRSS2-ERG fusion-positive prostate cancer; 3) Overexpressed genes in TMPRSS2-ERG fusion-positive prostate cancer
cells; 4) miRNA mediated regulation of the androgen receptor (AR) and its associated protein network; 5) Quantitative
control of ERG in prostate cancer cells; 6) TMPRSS2-ERG encoded protein targeting; In conclusion, we provide a detailed
understanding of TMPRSS2-ERG fusion related information in prostate cancer development to provide a rationale for
exploring TMPRSS2-ERG fusion-mediated molecular network machinery.Introduction
Multiple molecular signaling pathways overlap, integrate
and promote the progression of intraepithelial neoplasia
and metastasis. Accumulating evidence has shown that
genomic rearrangements play a vital role in regulating
differentiation, cell proliferation and invasive growth of
prostate cancers [1]. Recently, the fusion genes from the
ETS transcription factors like v-ets erythroblastosis virus
E26 homolog (avian) (ERG) were identified and reportedly
upregulated in an androgen-dependent manner [2]. The
fusion gene-positive cells may transform their phenotypes
from indolent and local nodules to a more aggressive and
less differentiated type of prostate cancer cells [1]. This
review mainly focuses on the representation of signaling* Correspondence: ammadahmad638@yahoo.com; changhw@kmu.edu.tw
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tate cancer cells. In addition, it also provides information
about broadening landscape of over-expressed androgen
receptor (AR) through loss of control of miRNA subsets.Genomic instability
Previous findings have linked aberrant genomic rearrange-
ments to tumor development. During tumorigenesis,
malignant cells not only carry somatic mutations from the
founder cell but also contain other acquired mutations
from daughter cells. Moreover, DNA damage repair
ignaling involved in androgen treated prostate cancer
cells. Androgen treatment can activate Ataxia telangiecta-
sia mutated (ATM) and Ataxia telangiectasia and Rad3
related (ATR) in the immortalized normal prostate epithe-
lial HPr-1 AR cells. Moreover, knockdown of ATM and
ATR in HPr-1 AR cells can induce transmembrane prote-
ase, serine 2 and ERG (TMPRSS2-ERG) fusion transcript
[3]. Additionally, androgen ablation can downregulate thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment of activation-induced cytidine deaminase (AID)
and LINE-1 repeat-encoded ORF2 endonuclease for
TMPRSS2:ERG rearrangements [5]. Certain hints have
emerged suggesting that androgen signaling induced
co-recruitment of AR and TOP2B topoisomerase
(DNA) II beta 180 kDa (TOP2B) at genomic break-
points of TMPRSS2-ERG, where TOP2B mediated
double stranded breaks and triggered this rearrangements
[6]. Mechanistically it was shown that AR bound to mul-
tiple intronic regions near break sites in TMPRSS2 and
ERG, suggesting that AR mediated juxtapositioning of
DNA breaks was essential for recombination and these
genomic rearrangements appears to be nonrandom [7,8].
ERG-overexpressing cancer cells demonstrated higher
single-strand break repair (SSBR) rate and leaded to radi-
ation resistance [9]. It is intriguing to note that knockdown
of PARP1 poly (ADP-ribose) polymerase 1 (PARP1) in
ERG-positive prostate cancer PC3 and DU145 cells may
resensitize radioresistant cancer cells. Targeted inhibition
of a DNA SSBR protein (XRCC1) by siRNA in ERG-
overexpressing cancer cells may impair ERG induced SSBR
and partially resensitize the cell radoresistance. In a xeno-
graft model, PARP1 inhibitor ABT-888 can recover the
ERG conferring radioresistance [9].
Prostate cancer and precursor lesions
Moreover, it is becoming clear that high-grade prostatic
intraepithelial neoplasia (HGPIN) is a precursor of some
prostate carcinomas, and thus is often characterized by
TMPRSS2-ERG fusion gene [10-12]. HGPIN is composed
of benign prostatic acini lined by cells with a malignant
phenotype, and prostate carcinomas may have zones of
HGPIN from which glands harboring carcinoma originate.
It is worth noting, prostates with carcinoma have more of
these hallmark foci than those without carcinoma. Pros-
tate glands with extensive HGPIN have more multifocal
carcinomas at the same time. Development of HGPIN
lesions occurs predominantly in the peripheral zone of the
prostate, which is believed to be the primary site of origin
for most adenocarcinomas. This is in accordance with the
fact that HGPIN lesions may initially be polyclonal prolif-
erations, with cells with TMPRSS2-ERG fusion being
diluted in a pool of cells which do not feature this alter-
ation. The HGPIN lesion may eventually be dominated by
the clone with the TMPRSS2-ERG fusion as a result of
clonal expansion, as evidenced by the analysis of ERG
overexpression in a subset of HGPIN lesions.
TMPRSS2-ERG fusion in prostate normal and cancer cells
New research results were reported that the TMPRSS2-
ERG fusion appears in late stage and in benign hyperplasia
[13] as well as in the normal margin of prostate tumors
[14-18]. For example, the detection of TMPRSS2-ERGfusion transcript were reported to 73% of primary prostate
tumor samples and 43% samples taken from non-malignant
tissues [19]. Accordingly, the levels of TMPRSS2-ERG fu-
sion transcript are correlated with the status of prostate
cells in normal or malignancy. In addition, it is noted that
different established prostate cancer cell lines may have dif-
ferent statuses for TMPRSS2-ERG. For example, the hu-
man prostate cancer VCaP cells are TMPRSS2-ERG
positive with wild type AR, whereas human prostate cancer
LNCaP cells are TMPRSS2-ERG negative with mutated AR.
The methylation may play an important role in regulat-
ing the TMPRSS2-ERG fusion. For example, it was re-
ported that fusion negative tumors are heavily methylated
as compared to fusion positive samples in terms of meth-
ylated DNA immunoprecipitation sequencing [20]. The
enhancer of zeste homolog 2 (Drosophila) (EZH2), a his-
tone methyltransferase, was upregulated in fusion negative
prostate tumor and controlled by miR-26a. Additionally,
SPINK1 overexpression has a tight correlation with small
deletions of 6q15- and 5q21 in ERG negative prostate can-
cers [21]. Loss of CDKN1B/p27Kip1 expression was ob-
served in subset of ERG-negative, low-grade tumors [22].
In contrast, FOXP2 forkhead box P2 (FOXP2) and nibrin
(NBN or NBS1) are overexpressed in fusion negative pros-
tate cancer cells [23,24].
Accordingly, These results suggested that the TMPRSS2:
ERG fusion is nonrandom in genomic level but may be
random in cell type level. In the next section we will briefly
discuss difference of TMPRSS2-ERG positive and negative
prostate cancer cells and how gene networks are regulated
in fusion positive cancer cells.Signal transduction cascades in fusion-positive prostate
cancer
Prostate cancer is developed through a series of specific
genetic alterations. It requires initial clonal expansion,
genomic instability, inactivation of tumor suppressor
genes, overexpression of oncogenes, and disruption of
the spatial-temporal behavior of signaling cascades [25].
With the landmark identification of a recurrent gene
fusion event on chromosome 21 between the TMPRSS2
and ERG genes, prostate cancers are now categorized as
"fusion-positive" and "fusion-negative" [12]. Following
genomic rearrangement, the expression of transcription
factor ERG may be regulated through the promoter of
the androgen-responsive gene TMPRSS2. For example,
TMPRSS2-ERG fusion products can bind to the ERG
locus and result in an overexpression of wild-type ERG.
Interestingly, polycomb proteins can modulate the
hypermethylation of ERG promoters in prostate cancer
cells, which also indicates the ERG gene is a hotspot of
DNA methylation, especially for tumors with DNA
methylation of ERG [26].
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resulted in notably downregulated wild-type ERG, whereas
stable transfection of TMPRSS2-ERG in the TMPRSS2-
ERG deficient PC3 cells resulted in upregulation of wild-
type ERG transcript. This experimental data provides a
direct evidence that ERG is overexpressed in fusion posi-
tive prostate cancer cells [27]. There are divergent pieces
of evidence suggesting regulation of AR by ERG. For
example, ERG signaling did not exert repressive effect on
AR expression of ERG-negative and moderate ERG
expressing prostate cancer cells [28]. In contrast, another
study indicated ERG can bind to AR and suppress AR
expression in prostate cancer VCaP cells [29]. Additionally,
androgen treatment can initiate TMPRSS2-ERG fusion in
both prostate normal and tumor cells [30]. The in vivo
growth of xenografts was propagated by serial transplant-
ation on male nude mice to explore a correlation between
TMPRSS2-ERG fusion and androgen. It was observed that
all androgen-dependent xenografts presented an overex-
pression of TMPRSS2-ERG. Moreover, although xenografts
carrying AR-negative tumors harbor a TMPRSS2-ERG
fusion gene, the fusion gene is not expressed [31].
TMPRSS2-ERG fusion-positive prostate cancer cells
show increased expression of several proliferation-related
genes than do fusion-negative prostate cancer cells. More
importantly, TMPRSS2-ERG fusion redirects these genes
under androgen regulation, while chemical castration and
anti-androgens downregulate one-half of these genes, and
decrease the transcriptome differences between fusion-
positive and -negative cases [32]. In addition, targeted
inhibition of the enzymes responsible for conversion of tes-
tosterone to dihydrotestosterone (DHT) in TMPRSS2-
ERG fusion-positive VCaP cells substantially decreased
proliferation and invasion. In vivo studies confirmed that
the combined treatment of dutasteride (a 5α-reductase
inhibitor) and anti-androgen bicalutamide extensively re-
pressed the tumor burden in xenograft animal studies [33].
Various signal transduction cascades were deregulated in
fusion-positive prostate cancer patients. Overrepresented
genes from the WNT and transforming growth factor, beta
1 (TGFB1)/bone morphogenetic protein (BMP) transduc-
tion cascades were validated [34] in the public gene expres-
sion database of prostate tumors [35]. In addition, various
tumor suppressors including p53, phosphatase and tensin
homolog (PTEN), breast cancer 1, early onset (BRCA1)
and BRCA2 are frequently truncated as a result of genomic
rearrangements in prostate cancer progression. Other
studies have indicated that genomic rearrangements re-
sulted in repression of tumor suppressor genes [36].
Peroxiredoxins 3 (PRDX3) and PRDX4 have been
found to be upregulated in prostate cancer tissue and
impact the cell growth of prostate tumors. Furthermore,
upregulation of PRDX3 and PRDX4 is negatively corre-
lated with the level of the TMPRSS2-ERG gene fusion[37]. Chromatin immunoprecipitation (ChIP) performed
in ERG-overexpressing RWPE cells (a normal prostate
cell line with low endogenous ERG) was found to valid-
ate that ERG recruited poly (ADP-ribose) polymerase 1
(PARP1) and protein kinase, DNA-activated, catalytic
polypeptide (DNA-PKcs) into co-existing complexes at
ERG-regulated loci [38]. Other experiments have verified
that ETS upregulation in primary prostate epithelial cells
induce DNA double strand breaks in terms of γ-H2AX foci.
Interestingly, targeted inhibition of endogenous ERG de-
creased the elevated levels of γ-H2AX. It is noteworthy that
pharmacological inhibition of PARP amplified the DNA
damage response in ETS-positive cancer cells. Simultan-
eously, PARP inhibition was found to severely compromise
ERG-mediated invasion and intravasation by abrogation of
ERG-mediated mRNA induction of progression-associated
genes such as EZH2 [38].
The vitamin D metabolism also reportedly modulates
the role of TMPRSS2-ERG in prostate tumorigenesis. For
example, some indications have emerged that prostate tu-
mors with high levels of vitamin D (1,25-dihydroxyvitamin
D3) receptors (VDR) are twice as likely to be TMPRSS2-
ERG fusion-positive than those with the low VDR levels
[39]. Cells treated with VDR agonist EB1089 demonstrated
genesis of TMPRSS2-ERG in both AR-negative as well as
in AR-positive cells [40].
Using hTERT/shp53/CDK4 to immortalize the primary
prostate epithelial (EP) cells reportedly forms tumors in an
in vivo model [41]. In contrast, AR-transfected (EP-AR)
cells formed distinct nodules in the prostate. In addition,
TMPRSS2-ERG-transfected EP-AR cells formed large ma-
lignant tumors. Interleukin 1 receptor, type II (IL1R2) and
serine peptidase inhibitor, Kunitz type 1 (SPINT1) are up-
stream regulators of zinc finger E-box binding homeobox
2 (ZEB2) expression thus respectively upregulating and
repressing ZEB2. ChIP assay revealed TMPRSS2-ERG
bound promoters of IL1R2, SPINT1 and ZEB1 genes, all of
which were found to contain possible TMPRSS2-ERG
binding sites. Overall, TMPRSS2-ERG directly binds and
trans-activates ZEB1 while SPINT1 and IL1R2 respectively
trans-activate and trans-repress to indirectly trigger ZEB2
expression [41].
Overexpression of an oncogenic ETS protein is in-
volved in the majority of prostate tumorgenesis [42].
Genome-wide binding analysis has progressively en-
hanced our understanding of over-expressing ETS pro-
teins by chromosomal rearrangement. RAS/ERK target
genes were reported to bind to ETS/AP-1 sequences and
become activated by oncogenic ETS proteins without
activation of the RAS/ERK pathway [43]. Accordingly,
upregulation of oncogenic ETS proteins can substitute
for the RAS/ERK pathway activation in prostate cells
[42]. This finding is important because fusion-positive
prostate cancer cells can express the target genes of the
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options.
Prostate-specific membrane antigen (PSMA) is upregu-
lated in the adenocarcinoma of prostate cancer.
TMPRSS2-ERG positive cells have a different gene net-
work as treatment of VCaP cells with androgen analog re-
sulted in the suppression of PSMA [44]. It was reported
that ERG overexpression and nuclear translocation can
activate Wnt signaling. However, treatment of prostate
cancer cells with the analogue of 3,3'-diindolylmethane
(BR-DIM) and curcumin inhibited AR/TMPRSS2-ERG/
Wnt signaling [45]. In addition, ERG-positive prostate
cancers are strongly histone deacetylase 1 (HDAC1)-
positive and there is an over-expression of wingless-
type MMTV integration site family (WNT)-associated
pathways and the simultaneous suppression of tumor
necrosis factors and cell death pathways [46]. Moreover,
ERG overexpression increased the frizzled family receptor
4 (FZD4) expressions whereas ERG null cells declined in
FZD4 at both the mRNA and protein levels. Laboratory
investigations indicated that spatial-temporal behavior of
the Wnt signaling pathway was disrupted in fusion-
positive prostate cancer cells. This was verified using the
T-cell factor/lymphoid enhancer factor (TCF/LEF) GFP
Reporter Assay in GFP-ERG-transfected RWPE1 cells.
The results clearly presented a 2.4-fold increase in WNT
signaling in response to ERG overexpression and, contrar-
ily, activity of the WNT pathway was decreased 3-fold by
the targeted inhibition of ERG [47].
This section has focused on fusion-positive prostate
cancer cells, which have misrepresented signaling cascades.
We have described current research of the cell-type-
specific genome-wide binding patterns of ERG and regu-
lating mechanisms by TMPRSS2-ERG encoded fusion
products in prostate cancer cells. Signaling components of
linear pathways were identified, including membrane
receptors and transcription factors, in an exploration of its
molecular mechanisms. In general, various signaling path-
ways are dysregulated in TMPRSS2-ERG fusion-positive
prostate cancer cells.
Direct binding of ERG can be validated by several
methods, such as in vitro binding assays [48], promoter
assays, and ChIP/polymerase chain reaction [49]. Other
approaches such as ChIP with promoter array analysis
(ChIP-chip) [50] and ChIP followed by sequencing (ChIP-
seq) [49] also provide robust analyses for the genome-wide
mapping of protein-binding patterns. In addition, using
promoter-tiling arrays provides a remarkably improved
chromatin-binding landscape of downstream effectors of
multiple signal transduction cascades which may help to
co-ordinate the prostate tumorigenesis. Genome-wide ana-
lyses are very important in cancer research and allow for
the clarification and stratification of the detailed mecha-
nisms for progression in prostate cancer.Recent work showed ubiquitin ligase, such as ring fin-
ger and WD repeat domain 2, E3 ubiquitin protein ligase
(RFWD2; COP1), functions as the tumor suppressor and
also downregulates the ets variant 1 (ETV1), ETV4 and
ETV5. However, it is worth noting that the truncated
ETV1 encoded by TMPRSS2:ETV1 loses the major
RFWD2 binding ability and becomes more stable than
its wild-type counterpart. Animal model studies further
verified that RFWD2 deficiency upregulated ETV1 level
and enhanced uncontrolled cellular growth and early
stage of prostate malignancy [51].
Overexpressed genes in fusion-positive prostate cancer cells
Recent research in prostate cancer biology has further
clarified that ERG is up-regulated in the glands of the
peripheral zone as compared to the transitional zone
[52]. Analysis of the deregulated genes indicated that
fusion-negative prostate tumor tissues were more similar
to normal controls, while fusion-positive prostate tumor
tissues displayed distinct deregulation of transcription.
Convergence of information suggests that different
genes are tightly inter-connected with the occurrence of
fusion transcripts in prostate cancer. We call attention
to the biological and clinical features of oncogenic ERG
and the therapeutic strategies in targeting the ERG net-
work. For example, cysteine-rich secretory protein 3
(CRISP3) gene expression was found to be associated
with the ERG condition, since it was overexpressed in
TMPRSS2-ERG fusion-positive prostate tumors as com-
pared to normal tissue. Laboratory findings indicated
that CRISP3 is a direct target of ERG and is strongly
overexpressed in prostate cancers with the TMPRSS2-
ERG fusion gene [53]. Consistently, the pim-1 oncogene
(PIM1) is a serine/threonine kinase which is frequently
upregulated in prostate cancer. Chip assays demon-
strated that TMPRSS2-ERG was found to be directly at-
tached to the PIM1 promoter. Overexpression of PIM1
induced by TMPRSS2-ERG upregulation considerably
modified cyclin B1 levels and the targeted inhibition of
TMPRSS2-ERG suppressed PIM1 induction [54]. ERG
target genes such as calcium channel, voltage-dependent,
L type, α-1D subunit (CACNA1D) were significantly up-
regulated in TMPRSS2-ERG positive prostate cancer cells
[39]. Osteopontin (OPN) is an extracellular matrix glyco-
phosphoprotein involved in the metastasis. Using in vitro
and in vivo molecular assays, it was reported that ERG
stimulates OPN expression through targeting ETS binding
sites in the OPN promoter. Transient transfection of
TMPRSS2-ERG in prostate cancer cells stimulated en-
dogenous OPN expression [55].
ETS RNA interference strategies were used to confirm
that ETS affected the levels of seven tumor-associated
ERG target genes, including phospholipase A1 member
A (PLA1A), calcium channel, voltage-dependent, L type,
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lipid transporter, class I, type 8A, member 2 (ATP8A2),
major histocompatibility complex, class II, DM beta
(HLA-DMB), phosphodiesterase 3B, cGMP-inhibited
(PDE3B), tudor domain containing 1 (TDRD1), and trans-
membrane BAX inhibitor motif containing 1 (TMBIM1)
and two tumor-associated ETV1 target genes (FK506
binding protein 10, 65 kDa (FKBP10) and glycine-N-
acyltransferase-like 2 (GLYATL2) [56].
TMPRSS2-ERG encoded fusion products were reported
to induce the expression of TLR4 [57]. Using BPH-1 and
RWPE-1-fERG cells, ERG level was found to be associated
with the overexpression of integrin-linked kinase (ILK)
and its downstream effectors zinc-finger transcription fac-
tor Snail and lymphoid enhancer-binding factor 1 (LEF1).
Targeted inhibition of ERG may downregulate the ILK,
Snail and LEF1 gene expressions [58]. Mechanistic target-
ing of rapamycin (serine/threonine kinase) (mTOR) sig-
naling is also activated in fusion-positive prostate cancer
cells. Loss of pSer-2448 mTOR resulted in the full activa-
tion of Mtor [59]. c-myc is overexpressed in TMPRSS2-
ERG fusion-positive prostate cancer cells as compared to
normal tissue [60]. However, c-myc is also overexpressed
in fusion negative tumors as compared to normal tissue
[20]. Therefore, the relationship between c-myc and
TMPRSS2-ERG fusion is still warranted to further investi-
gate. Furthermore, fusion-positive prostate cancer cells
were reported to downregulate frizzled receptors, overex-
press the Rho GDP-dissociation inhibitor (RhoGDIB) [61],
and overexpress the SRY (sex determining region Y)-box
9 (SOX9) gene [62].
Cellular studies suggest that recruitment of ERG pro-
motes local H3K4 methylation and the subsequent bind-
ing of forkhead box A1 (FOXA1). FOXA1 is essential for
androgen-stimulated binding of AR to the target genes
[62]. Furthermore, ERG enhances the expression of vari-
ous genes by controlling the methylation status of the pro-
moter region of the target genes. For example, Tudor
domain-containing protein 1 (TDRD1) was found to
differentially regulate between fusion-positive and fusion-
negative prostate cancer cells. The promoter of TDRD1 is
hypomethylated and TDRD1 becomes overexpressed in
ERG overexpressing prostate cancer cells [63]. It has lately
been shown that phosphorylated ERG regulated expres-
sion of chemokine (C-X-C motif) receptor 4 (CXCR4) in
prostate cancer cells. The I kappa B (IKK) and AKT
kinases were noted to phosphorylate ERG at Serine 81
and 215, respectively [64], which were identified by their
inhibitors such as BMS34551 and AKT Inhibitor IV.
The migratory and invasive potential of prostate cancer
cells was noted to be regulated by ERG mediated expres-
sion of Metalloproteinase 9 and Plexin A2 [65]. Increas-
ingly it is being realized that ligand independent activation
of AR is regulated in CACNA1D overexpressing prostatecancer cells. Mechanistically it was reported that ERG
induced expression of CACNA1D promoted entry of cal-
cium ions into cytosol [66].
The above explains how TMPRSS2-ERG encoded fusion
products impair cell cycle checkpoints and promote pro-
liferation. It appears that fusion-positive prostate cancer
cells have a well-orchestrated network of coactivators and
co-repressors, and that dysregulated signaling cascades
also crosstalk and contribute in carcinogenesis. Next we
address the quantity control of AR, ERG and the regula-
tory machinery of AR signaling.
miRNA mediated regulation of the androgen receptor
and its associated protein network
It is well known that overexpression of AR contributes
to antiandrogen resistance by amplifying signal output,
and by changing the regular response to antagonists
[67]. However, it is also important to mention that the
loss of AR regulating miRNA signatures is a central aspect
that underlies AR overexpression. In following section we
discuss AR regulation by subsets of miRNA and their
expression patterns in cancer cells.
It has reported that androgen-induced AR binds to the
miR-21 promoter, signifying direct transcriptional regula-
tion and considerable prostate carcinogenesis. However,
inhibition of miR-21 decreased uncontrolled cellular pro-
liferation [68].
A recent study has indicated that various miRNAs act
as tumor suppressors and transiently transfecting cells
with miR-331-3p reduced phosphorylated v-akt murine
thymoma viral oncogene homolog 1 (AKT1) content [69].
Animal model studies verified that crossing TMPRSS2-
ERG mice with prostate-specific AKT transgenic mice
generated bigenic mice that developed more florid lesions.
It is therefore now well acclaimed that TMPRSS2-ERG fu-
sion alone is not enough to induce prostate intraepithelial
neoplasia (PIN) but co-existence/co-occurrence of hetero-
zygous Pten deletion in fusion positive cells dramatically
promotes PIN [70].
In addition the v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2, neuro/glioblastoma derived onco-
gene homolog (avian) (ERBB2) is another important
receptor that is dysregulated in prostate cancer [69].
Contradictory findings have been presented regarding the
role of this receptor in prostate cancer. It was reported
that overexpression of ERBB2 activated AR pathway in
prostate cancer cells in an androgen-deficient milieu [71].
However, ERBB-2 reportedly decreases the expression of
endogenous AR and androgen-regulated PSA in LNCaP
cells [72]. Truncated androgen receptors in prostate
cancer 22Rv1 cells can bind DNA in the absence of ligand
and repress the ERBB2 gene repression and for the 22Rv1
cell castration resistant phenotype [73]. Notably, targeted
inhibition of ERBB2 effectively degraded AR and reduced
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Another research group has indicated that ERBB2/ERBB3
can maintain AR protein levels and ERBB2/ERBB3 were
found to be attached to the promoter/enhancer of andro
gen-regulated genes in hormone-refractory prostate can-
cer [75]. ERBB2 and ERBB3 considerably increase the
androgen-dependent AR transactivation of reporter genes
in prostate cancer cells [76]. Targeted inhibition of ERBB2
kinase severely impaired androgen receptor recruitment
to the androgen responsive enhancer in LNCaP cells [77].
Given that miR-331-3p represses ERBB2 expression
and signal transduction in prostate cancer cells it seems
reasonable to note that ERBB2 targeting destabilizes AR.
However negative regulation of ERBB2 by miRNA is an-
tagonized by the U-rich element located near the distal
miR-331-3p target site in the ERBB2 3'-untranslated re-
gion (UTR). A detailed mechanistic investigation indicated
that specific binding of the RNA binding protein- ELAV
(embryonic lethal, abnormal vision, Drosophila)-like 1
(Hu antigen R) (HuR; ELAVL1) to this U-rich element
momentously enhanced ERBB2 expression in prostate
cancer cells [69,78]. The 3-UTR of AR mRNA contains
UC-rich consensus regions such as 5'-C(U)(n)C motif and
a 3'-CCCUCCC poly(C)-binding protein motif. Analysis of
the UC-rich region indicated the presence of a specific
binding motif for ELAVL1 [79]. Enforced expression of
the miR-34a precursor into paclitaxel resistant prostate
cancer cells resulted in decreases in ELAVL1 [80]. Xeno-
grafting miR-34a competent prostate cancer cells in nude
mice notably repressed tumor growth as miR-34a sup-
pressed the assembly and function of the c-Myc-Skp2-
Miz1 complex [81]. Therefore, it is understandable that
miRNA mediated control of AR is lost in TMPRSS2-ERG
positive prostate cancer and ELAVL1 stabilizes the expres-
sion of AR and ERBB2 which synchronously trigger the
expression of cancer promoting genes.
Interestingly, over-expression of constitutively active
AKT results in a proliferative advantage. Contrary to the
proliferation enhancing potential of AKT, over-expression
of ERG promoted cellular migration. ERG triggered the
migratory potential of cancer cells by the overexpression
of CXCR4 and ADAM metallopeptidase with a thrombos-
pondin type 1 motif, 1 (ADAMTS1) as ChIP assay demon-
strated direct binding of ERG to the promoter region for
both CXCR4 and ADAMTS1 [82]. In the CXCR4 pro-
moter, several consensus sequences of ERG binding sites
were identified and it was noted that an androgen agonist
(R1881) can induce the mRNA expressions of both ERG
and CXCR4 genes in TMPRSS2-ERG fusion-positive
VCaP cells. Conversely, targeted inhibition of ERG by
siRNA can inhibit the gene expressions of ERG and
CXCR4 and prevents the upregulation of the androgen-
induced CXCR4 expression in VCaP cells [83]. However,
it is also relevant to mention that CXCR4 is negativelyregulated by miR-139. Use of antagomirs against miR-139
rescued the CXCR4 expression. Gastric cancer cells were
reported to use a specific mechanism to repress the ex-
pression of miR-139 via the interaction of ERBB2 with
CD44 [84]. A conflicting report suggests that no relation-
ship exists between CXCR4 mRNA overexpression and
TMPRSS2-ERG [85].
Notably, androgen and AR can transcriptionally and
post-transcriptionally regulate the MiR-23a27a24-2 cluster
in prostate cancer cells [86]. For example, in response to
androgen, AR was reported to associate with the miR-
23a27a24-2 promoter, initiate its transient transcription,
and enhance androgen-induced processing from primiR-
23a27a24-2 to its mature form premiR-23a27a24-2. In
particular, miR-27a can negatively regulate a corepressor
of AR, namely prohibitin, and has therapeutic potential
for prostate cancer.
Furthermore, miR 488 [87] and miR-let-7c [88] reportedly
downregulate the transcriptional activity of AR. miR-133
can negatively regulate the epidermal growth factor receptor
(EGFR) [89]. miR-130a, miR-203 and miR-205 work syn-
chronously to target components involved in mitogen acti-
vated kinase-like protein (MAPK) and AR signaling
pathways [90]. It is noteworthy that isoflavone demethylates
the methylation status in the promoter of miR-29a and
miR-1256, resulting in an overexpression of miR-29a and
miR-1256, which can directly target the tripartite motif con-
taining 68 (TRIM68) [91]. TRIM68 interacts with AR and
enhances transcriptional activity of the AR target genes [92].
A recent report suggests that AR and the heterogeneous
nuclear ribonucleoprotein K (HNRNPK) colocalize in the
nucleoplasm and both were synchronously regulated by
bicalutamide and/or 4-hydroxy-tamoxifen (BIC/4OHT)
treatment [93]. Functional HNRNPK binding sites were
reported to locate in 5'-UTR of AR mRNA. Further ana-
lysis revealed that HNRNPK can inhibit translation of the
truncated AR without 5'-UTR, as additional HNRNPK
binding sites were located at the AR open reading frame
and its 3'-UTR [94]. HNRNPK and VEGF-A are direct tar-
gets of miR-205 and miR-29b, respectively [95]. Similarly,
CD44 and v-akt murine thymoma viral oncogene homo-
log 2 (AKT2) are direct targets of miR-708 [96].
Next we discuss the tissue-specific miRNA control of
PTEN in several cancer cells. Previous reports have shown
that different miRNA subsets modulate PTEN, thus restor-
ing the cancer promoting functionality of AKT. Various
tissue-specific studies show PTEN was negatively regulated
by several miRNAs, e.g., miR-21, miR-221 and miR-222 in
gastric cancer [97,98]; miR-93 in ovarian cancer [99]; miR-
519d in liver cancer [100]; miR-214 in non-small cell lung
cancer [101]; and miR-153 [102] and miR-21 [103] in pros-
tate cancer.
We currently lack a complete understanding of the
mechanisms which promote loss of PTEN in fusion-
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standing of PTEN targeted miRNA-network would be of
immense interest. Intriguingly, a recent study indicated
that prostate cancer cells treated with resveratrol displayed
down regulated miR-17-92, miRs-106a and miRs-106b
oncogenic clusters, thus upregulating PTEN [104].
Quantitative control of ERG in prostate cancer cells
Evidence exists that ERG interferes AR signaling by inhi-
biting AR expression via recruiting H3K27 methyltransfer-
ase, a Polycomb group protein named as enhancer of
zeste homolog 2 (Drosophila) (EZH2) [29]. Increasingly it
is being recognized that targeted inhibition of ERG in the
hormone-starved VCaP cells significantly repressed the
expression of EZH2 and increased the expression of AR
protein [29]. EZH2 is negatively regulated by miR-101 as
genomic loss of miR-101 in the cancer leads to the upreg-
ulation of EZH2 [105]. EZH2 is also targeted by the let-7
family of microRNAs and prostate cancer cells pretreated
with BR-DIM displayed an up-regulated let-7 family and
down-regulated EZH2 expression [106]. Furthermore,
there is significant proof that miR-196a and miR-196b
negatively regulate ERG [107]. Fitting together the scat-
tered pieces of this jigsaw puzzle indicates that the dis-
turbance of miRNA mediated regulation of ERG and
EZH2 in prostate cancer requires detailed investigation.
TMPRSS2-ERG encoded protein targeting
The treatment of prostate cancer is being revolutionized
by an improved comprehension of the genetic events that
occur in the progression of the disease. These TMPRSS2-
ERG encoded fusion products and DNA interactions have
been investigated that explore the contribution of these
proteins to oncogenesis and therapeutic resistance.
It has been convincingly demonstrated that heterocyclic
diamidine specifically targets part of the ERG DNA recog-
nition site [48]. It is encouraging to note an increased
interest in inducing apoptosis in fusion-positive prostate
cancer cells and disulfiram/sunitinib cotreatment induced
apoptosis in TMPRSS2-ERG fusion-positive VCaP pros-
tate cancer cells [108]. RNA interference strategies are
also being used to target the T/E fusion junction in vivo
with specific siRNAs delivered via liposomal nanovectors,
a promising therapy for prostate cancer [109]. Using
cDNA arrays, several gene transcripts that potentially
cause TMPRSS2-ERG gene fusion were identified as being
effectively downregulated by curcumin. Furthermore, cur-
cumin reportedly inhibited expressions of EGFR and
ERBB2 receptors in prostate cancer cell lines [110]. High
throughput technologies have provided potential com-
pounds which are effective in inhibiting ERG and ETV1
mediated transcription in a reporter assay. Using this ap-
proach, it was reported that the inhibitor of the EWS-
FLI1 oncoprotein in Ewing’s Sarcoma (YK-4-279) candownregulate the gene expressions of ERG and ETV1
downstream target genes in ETV1 or ERG fusion-positive
prostate cancer cells. More interestingly, ERG inhibition
by siRNA was unresponsive to YK-4-279 in VCaP cells
[111]. The traditional Chinese herbal medicine cryptotan-
shinone (CTS) was reported to be an AR inhibitor, sup-
pressing androgen/AR-mediated cell proliferation and
PSA expression through a remarkably effective inhibition
of AR dimerization. CTS efficiently suppress the cell
growth of castration resistant cells and the DHT-induced
AR target genes (PSA, TMPRSS2, and TMEPA1) in the
VCaP-luciferase xenograft mouse model [112].
ERG binds and inhibits histone acetyltransferases,
resulting in the abrogation of p53 mediated expression
of p21 and Bax. However, HDAC is active in fusion-
positive prostate cancer cells. Intriguingly, experiments
in ERG-positive VCaP cells treated with HDAC inhibi-
tors, e.g., valproic acid and trichostatin-A, can induce
apoptosis, enhance p53 acetylation, induce p21/Waf1/
CIP1, and inhibit TMPRSS2-ERG expression [113].
Similarly, HDAC inhibitors were reported to inhibit the
ERG-fusion gene expression, whereas the trichostatin-A
significantly inhibits the ERG-associated gene signature.
Synergistic administration of HDAC inhibitors (Trichosta-
tin A, MS-275 and suberoylanilide hydroxamic acid) and
AR antagonists (flutamide) result in the cytoplasmic re-
tention of AR, indicating inhibition of androgen signaling
[114]. Exposing ERG overexpressing and PTEN-deficient
prostate cancer cells to a combined treatment of PARP in-
hibitor (rucaparib) and radiation induced senescence. In
contrast, PTEN competent cells were treated to verify
whether a PTEN deficiency induced senescence, with re-
sults indicating that PTEN sufficient DU145 cells showed
almost no senescence. Moreover, rucaparib combined
with a low dose radiation may induce persistent DNA
damage in terms of γH2AX foci and considerably reduced
cell survival [115]. Celastrol is a well-known NF-kB inhibi-
tor and oncogenic fusion protein. Expressing prostate can-
cer cells pretreated with celastrol was reported to dose-
dependently inhibit TMPRSS2-ERG fusion, AR and AR3
gene expression [116]. There is a direct evidence suggest-
ing that a deubiquitinase namely ubiquitin-specific peptid-
ase 9, X-linked (USP9X) can regulate the ERG protein
expression in prostate cancer VCaP cells. For example,
USP9X inhibitor (WP1130) downregulated ERG levels
and inhibited cell proliferation and migration in prostate
tumors. WP1130 also considerably abrogated tumor
angiogenesis in ERG-overexpressing VcaP cells xenograft
nude mice [117].
On the TRAIL of TMPRSS2-ERG encoded fusion products
targeting
New experimental and preclinical data suggests that the
tumor necrosis factor (ligand) superfamily, member 10
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Structural studies have shown that DR4 and DR5 contain
the intracellular death domain (DD) which is required for
apoptosis following receptor ligation. Cancer cells also dis-
play decoy receptor 1 (DcR1) and DcR2 and these are un-
able to cause apoptosis due to a complete or partial
deletion of the intracellular DD, respectively [118-120].
Despite considerable work to overcome TRAIL resistance
in prostate cancer cells, we still have no insight into the
mechanics of TRAIL mediated signaling in fusion-positive
prostate cancer cells. Recently, low levels of androgen are
reported to be potent inducers of apoptosis in prostate
cancer cells. DR5 was noted to be dramatically enhanced
in cancer cells treated with low levels of androgen. On the
contrary, pretreatment with high concentration of andro-
gen induced pro-survival signals in TRAIL treated pros-
tate cancer cells [121].
Contemporary studies suggested that HDAC inhibitor
(Trichostatin A) converted the phenotype of human pros-
tatic cancer cell line DU145 from resistant to sensitive.
Treatment with Trichostatin A can activate caspase-9 and
release mitochondrial cytochrome c and diablo, IAP-
binding mitochondrial protein (DIABLO; Smac) in TRAIL
resistant prostate cancer cells [122]. Similarly, HDAC inhibi-
tors (depsipeptide and MS-275) were reported to effectively
enhance TRAIL gene therapy of LNCaP prostate cancer
cells [123]. Suberolylanilide hydroxamic acid and TRAIL
synergistically induced apoptosis in LNCaP cells [124].
Conclusion
Genomic rearrangement has added another layer of
complexity to prostate cancer investigation and has been
emerged as major challenge to targeted therapeutic
research. Our understanding of the mechanisms which
act as triggers to genomic rearrangements is incomplete.
We still need to determine which signaling cascades are
misrepresented and contribute to genomic rearrange-
ments, and which tumor suppressor signaling pathways
are inactivated in fusion positive prostate cancer cells.
Furthermore, our understanding of the impairment of
apoptosis in TMPRSS2-ERG positive cancer cells is also
incomplete. Fuller understanding of the mechanisms
which inhibit pro-apoptotic proteins and promote anti-
apoptotic proteins would provide a significant gain
towards the development of personalized medicine.
TRAIL mediated signaling in rearranged prostate cancer
cells has not been adequately investigated, and a deeper
understanding of the death and decoy receptors in fu-
sion positive prostate cancer cells is essential to testing
of synthetic and natural compounds to restore TRAIL
mediated signaling in prostate cancer cells. Similarly,
fewer studies have investigated the targeting of different
signaling pathways in fusion positive prostate cancer
cells. Other important questions include how DNAdamage signaling regulates genomic rearrangements in
prostate cancer cells and how this DNA damage repair
signaling can be targeted to suppress genomic instability.
Research is also required to determine how DNA dam-
age inducing chemotherapeutic drugs contribute to the
genesis of genomic rearrangements in prostate cancer
cells. Recent improvements have been made in the
visualization and quantification of the components of
TMPRSS2-ERG signaling network [125], thus providing
a better picture of different signaling pathways in
TMPRSS2-ERG positive prostate cancer cells.
Functional interdependencies were explored between
the molecular components in fusion-positive prostate
cancer cells. The less appreciated facet of identification
of dysregulated protein network needs extensive re-
search to characterize the proteome of fusion-positive
prostate cancer cells. This approach can be used to sys-
tematically explore the molecular complexity and relation-
ships of fusion-positive prostate cancer cells. Furthermore,
advances in classification of many cancer promoting genes
and miRNA signatures for uncovering the biological
mechanism of oncogenic TMPRSS2-ERG fusions associ-
ated genomic changes have been summarized, along with
the drug targets and biomarkers for prostate cancer
development.
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